Published in J Biol Chem on July 10, 2007
Functions and mechanisms of action of CCN matricellular proteins. Int J Biochem Cell Biol (2008) 3.62
Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets. Nat Rev Drug Discov (2011) 3.26
From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocr Rev (2010) 3.11
CCN1/CYR61: the very model of a modern matricellular protein. Cell Mol Life Sci (2011) 1.75
Matricellular protein CCN1 promotes regression of liver fibrosis through induction of cellular senescence in hepatic myofibroblasts. Mol Cell Biol (2013) 1.47
Glucocorticoids, osteocytes, and skeletal fragility: the role of bone vascularity. Bone (2009) 1.11
Sclerostin binds and regulates the activity of cysteine-rich protein 61. Biochem Biophys Res Commun (2009) 1.05
Matricellular protein CCN1/CYR61: a new player in inflammation and leukocyte trafficking. Semin Immunopathol (2014) 1.04
Role of cysteine-rich 61 protein (CCN1) in macrophage-mediated oncolytic herpes simplex virus clearance. Mol Ther (2014) 0.94
Mechanical stability affects angiogenesis during early fracture healing. J Orthop Trauma (2011) 0.94
Substance P-mediated expression of the pro-angiogenic factor CCN1 modulates the course of colitis. Am J Pathol (2008) 0.92
Degradome products of the matricellular protein CCN1 as modulators of pathological angiogenesis in the retina. J Biol Chem (2013) 0.85
DJ-1 promotes angiogenesis and osteogenesis by activating FGF receptor-1 signaling. Nat Commun (2012) 0.85
Impaired angiogenesis during fracture healing in GPCR kinase 2 interacting protein-1 (GIT1) knock out mice. PLoS One (2014) 0.85
CCN3 modulates bone turnover and is a novel regulator of skeletal metastasis. J Cell Commun Signal (2012) 0.83
Delayed fracture healing and increased callus adiposity in a C57BL/6J murine model of obesity-associated type 2 diabetes mellitus. PLoS One (2014) 0.83
The matricellular protein CCN1 promotes mucosal healing in murine colitis through IL-6. Mucosal Immunol (2015) 0.80
Difference in intraosseous blood vessel volume and number in osteoporotic model mice induced by spinal cord injury and sciatic nerve resection. J Bone Miner Metab (2011) 0.79
Cyr61 silencing reduces vascularization and dissemination of osteosarcoma tumors. Oncogene (2014) 0.78
The Angiopoietin-1 Variant COMP-Ang1 Enhances BMP2-Induced Bone Regeneration with Recruiting Pericytes in Critical Sized Calvarial Defects. PLoS One (2015) 0.77
PDGF beta targeting in cervical cancer cells suggest a fine-tuning of compensatory signalling pathways to sustain tumourigenic stimulation. J Cell Mol Med (2014) 0.77
Cysteine-rich matricellular protein improves callus regenerate in a rabbit trauma model. Int Orthop (2012) 0.76
Mechanisms of angiogenesis. Nature (1997) 18.04
Angiogenesis in health and disease. Nat Med (2003) 14.02
VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med (1999) 9.18
Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci U S A (1998) 4.82
Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad Sci U S A (2002) 4.46
Bone development. Annu Rev Cell Dev Biol (2000) 4.24
The CCN family of angiogenic regulators: the integrin connection. Exp Cell Res (1999) 3.90
CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci U S A (1998) 3.18
CYR61 (CCN1) is essential for placental development and vascular integrity. Mol Cell Biol (2002) 2.94
Tensional forces in fibrillar extracellular matrices control directional capillary sprouting. J Cell Sci (1999) 2.71
Expression of cyr61, a growth factor-inducible immediate-early gene. Mol Cell Biol (1990) 2.64
Synergistic enhancement of bone formation and healing by stem cell-expressed VEGF and bone morphogenetic protein-4. J Clin Invest (2002) 2.59
Skeletal defects in VEGF(120/120) mice reveal multiple roles for VEGF in skeletogenesis. Development (2002) 2.57
Cyr61, a product of a growth factor-inducible immediate-early gene, promotes cell proliferation, migration, and adhesion. Mol Cell Biol (1996) 2.44
Conditional inactivation of VEGF-A in areas of collagen2a1 expression results in embryonic lethality in the heterozygous state. Development (2000) 2.43
Angiogenesis and bone repair. Drug Discov Today (2003) 2.26
CCN1/Cyr61 is regulated by the canonical Wnt signal and plays an important role in Wnt3A-induced osteoblast differentiation of mesenchymal stem cells. Mol Cell Biol (2006) 2.15
Pro-angiogenic activities of CYR61 (CCN1) mediated through integrins alphavbeta3 and alpha6beta1 in human umbilical vein endothelial cells. J Biol Chem (2002) 2.00
Angiogenesis and bone growth. Trends Cardiovasc Med (2000) 1.98
Cyr61 and Fisp12 are both ECM-associated signaling molecules: activities, metabolism, and localization during development. Exp Cell Res (1997) 1.88
Regulation of angiogenesis and endothelial cell function by connective tissue growth factor (CTGF) and cysteine-rich 61 (CYR61). Angiogenesis (2002) 1.84
Vascular endothelial growth factor stimulates chemotactic migration of primary human osteoblasts. Bone (2002) 1.72
Junctional adhesion molecule-C regulates vascular endothelial permeability by modulating VE-cadherin-mediated cell-cell contacts. J Exp Med (2006) 1.67
Cyr61, product of a growth factor-inducible immediate early gene, is associated with the extracellular matrix and the cell surface. Cell Growth Differ (1991) 1.55
Vasculotropin/vascular endothelial growth factor induces differentiation in cultured osteoblasts. Biochem Biophys Res Commun (1994) 1.55
Cyr61, product of a growth factor-inducible immediate-early gene, regulates chondrogenesis in mouse limb bud mesenchymal cells. Dev Biol (1997) 1.39
Is human fracture hematoma inherently angiogenic? Clin Orthop Relat Res (2000) 1.36
Expression of the growth factor-inducible immediate early gene cyr61 correlates with chondrogenesis during mouse embryonic development. Cell Growth Differ (1992) 1.36
The vascular contribution to osteogenesis. II. Studies with the electron microscope. J Bone Joint Surg Br (1960) 1.30
Temporal expression of the chondrogenic and angiogenic growth factor CYR61 during fracture repair. J Bone Miner Res (2000) 1.29
Anabolic effects of 1,25-dihydroxyvitamin D3 on osteoblasts are enhanced by vascular endothelial growth factor produced by osteoblasts and by growth factors produced by endothelial cells. Endocrinology (1997) 1.24
Regulation of neovascularization by human neutrophil peptides (alpha-defensins): a link between inflammation and angiogenesis. FASEB J (2004) 1.17
The extracellular adherence protein (Eap) of Staphylococcus aureus inhibits wound healing by interfering with host defense and repair mechanisms. Blood (2005) 1.07
Cyr61 mediates the expression of VEGF, alphav-integrin, and alpha-actin genes through cytoskeletally based mechanotransduction mechanisms in bladder smooth muscle cells. J Appl Physiol (1985) (2005) 1.04
Impairment of bone healing by insulin receptor substrate-1 deficiency. J Biol Chem (2004) 1.03
Impaired inflammatory angiogenesis, but not leukocyte influx, in mice lacking TNFR1. J Leukoc Biol (2005) 1.02
The role of microvasculature in normal and perturbed bone healing as revealed by intravital microscopy. Bone (1996) 0.99
Current concepts of bone healing. Clin Podiatr Med Surg (2001) 0.94
Skeletal site-dependent expression of the androgen receptor in human osteoblastic cell populations. Calcif Tissue Int (1997) 0.91
Proteolysis of CCN1 by plasmin: functional implications. Cancer Res (2005) 0.91
Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes. Blood (1998) 0.91
Relationships between endothelial cells, pericytes, and osteoblasts during bone formation in the sheep femur following implantation of tricalciumphosphate-ceramic. Anat Rec (1995) 0.89
Concerted action of androgens and mechanical strain shifts bone metabolism from high turnover into an osteoanabolic mode. J Exp Med (2002) 0.88
Expression of the angiomatrix and angiogenic proteins CYR61, CTGF, and VEGF in osteonecrosis of the femoral head. J Orthop Res (2006) 0.84
Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl) (2005) 4.96
Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest (2004) 3.89
A mechanism converting psychosocial stress into mononuclear cell activation. Proc Natl Acad Sci U S A (2003) 3.82
High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation (2008) 3.46
Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med (2007) 3.35
Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nat Med (2012) 3.31
Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol (2005) 3.05
The junctional adhesion molecule JAM-C regulates polarized transendothelial migration of neutrophils in vivo. Nat Immunol (2011) 3.04
The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med (2003) 2.94
Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res (2011) 2.53
RAGE signaling sustains inflammation and promotes tumor development. J Exp Med (2008) 2.51
The leukocyte integrin antagonist Del-1 inhibits IL-17-mediated inflammatory bone loss. Nat Immunol (2012) 2.48
A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J (2007) 2.44
RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol (2003) 2.43
The junctional adhesion molecule 3 (JAM-3) on human platelets is a counterreceptor for the leukocyte integrin Mac-1. J Exp Med (2002) 2.42
Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes (2008) 2.41
Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest (2003) 2.40
RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis (2008) 2.33
Atherogenic dyslipidaemia but not total- and high-molecular weight adiponectin are associated with the prognostic outcome in patients with coronary heart disease. Eur Heart J (2008) 2.26
Role of toll-like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo. Shock (2009) 2.26
Pharmacologic cholinesterase inhibition improves survival in experimental sepsis. Crit Care Med (2008) 2.18
A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis. Am J Pathol (2008) 2.17
[Do markers of bone metabolism reflect the presence of a high- or low-turnover state of bone metabolism?]. Med Klin (Munich) (2002) 2.10
Del-1, an endogenous leukocyte-endothelial adhesion inhibitor, limits inflammatory cell recruitment. Science (2008) 2.10
Complement-mediated inhibition of neovascularization reveals a point of convergence between innate immunity and angiogenesis. Blood (2010) 2.08
Role of beta2-integrins for homing and neovascularization capacity of endothelial progenitor cells. J Exp Med (2004) 2.04
Endothelial cell protein C receptor acts as a cellular receptor for factor VIIa on endothelium. J Biol Chem (2007) 2.01
Defective neutrophil recruitment in leukocyte adhesion deficiency type I disease causes local IL-17-driven inflammatory bone loss. Sci Transl Med (2014) 1.94
Cystine 186-cystine 209 disulfide bond is not essential for the procoagulant activity of tissue factor or for its de-encryption. Blood (2010) 1.92
Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. J Clin Invest (2004) 1.92
Sustained low efficiency dialysis using a single-pass batch system in acute kidney injury - a randomized interventional trial: the REnal Replacement Therapy Study in Intensive Care Unit PatiEnts. Crit Care (2012) 1.90
High-mobility group box 1 activates integrin-dependent homing of endothelial progenitor cells. Circ Res (2007) 1.89
The junctional adhesion molecule-C promotes neutrophil transendothelial migration in vitro and in vivo. J Biol Chem (2004) 1.89
Platelets contribute to the pathogenesis of experimental autoimmune encephalomyelitis. Circ Res (2012) 1.85
Low but sustained coagulation activation ameliorates glucose-induced podocyte apoptosis: protective effect of factor V Leiden in diabetic nephropathy. Blood (2011) 1.83
Selective abrogation of the uPA-uPAR interaction in vivo reveals a novel role in suppression of fibrin-associated inflammation. Blood (2010) 1.82
Glyoxalase-1 prevents mitochondrial protein modification and enhances lifespan in Caenorhabditis elegans. Aging Cell (2008) 1.81
Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration. Blood (2004) 1.80
Developmental endothelial locus-1 (Del-1) mediates clearance of platelet microparticles by the endothelium. Circulation (2012) 1.78
Relationship of adiponectin with markers of systemic inflammation, atherogenic dyslipidemia, and heart failure in patients with coronary heart disease. Clin Chem (2006) 1.75
RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J Am Soc Nephrol (2009) 1.72
Tissue factor-factor VIIa signaling. Arterioscler Thromb Vasc Biol (2004) 1.69
Junctional adhesion molecule-C regulates vascular endothelial permeability by modulating VE-cadherin-mediated cell-cell contacts. J Exp Med (2006) 1.67
Phosphatidylinositol-3-kinase-gamma is integral to homing functions of progenitor cells. Circ Res (2008) 1.65
RAGE (receptor for advanced glycation end products): a central player in the inflammatory response. Microbes Infect (2004) 1.63
Low plasma adiponectin levels are associated with increased hepatic lipase activity in vivo. Diabetes Care (2005) 1.62
Surgical versus medical treatment of type 2 diabetes mellitus in nonseverely obese patients: a systematic review and meta-analysis. Ann Surg (2015) 1.62
Bone morphogenetic protein (BMP) for fracture healing in adults. Cochrane Database Syst Rev (2010) 1.56
The neutrophil-specific antigen CD177 is a counter-receptor for platelet endothelial cell adhesion molecule-1 (CD31). J Biol Chem (2007) 1.53
Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. J Biol Chem (2008) 1.52
Regulation of integrin activity and signalling. Biochim Biophys Acta (2009) 1.51
Leukocyte-endothelial interactions in inflammation. J Cell Mol Med (2009) 1.51
Histone H2AX is integral to hypoxia-driven neovascularization. Nat Med (2009) 1.48
sRAGE is elevated in septic patients and associated with patients outcome. J Surg Res (2007) 1.47
AGE-modified albumin containing infusion solutions boosts septicaemia and inflammation in experimental peritonitis. J Leukoc Biol (2009) 1.45
The Case: Renal failure in a male with Waldenström's macroglobulinemia. Kidney Int (2010) 1.44
Evidence of left ventricular contractile asynchrony by echocardiographic phase imaging in patients with type 2 diabetes mellitus and without clinically evident heart disease. Am J Cardiol (2006) 1.44
Olfactory loss may be a first sign of idiopathic Parkinson's disease. Mov Disord (2007) 1.41
Nanocrystalline hydroxyapatite and calcium sulphate as biodegradable composite carrier material for local delivery of antibiotics in bone infections. Biomaterials (2005) 1.41
RAGE in inflammation: a new therapeutic target? Curr Opin Investig Drugs (2006) 1.40
Increased proinflammatory endothelial response to S100A8/A9 after preactivation through advanced glycation end products. Cardiovasc Diabetol (2006) 1.40
Extracellular matrix metalloproteinase inducer regulates matrix metalloproteinase activity in cardiovascular cells: implications in acute myocardial infarction. Circulation (2006) 1.40
Association of COLIA1 Sp1 polymorphism with the effect of subcutaneously injected recombinant hGH in GH-deficient adults. Pharmacogenomics (2008) 1.39
Vascular endothelial growth factor increases functional beta-cell mass by improvement of angiogenesis of isolated human and murine pancreatic islets. Transplantation (2005) 1.36
Factor VIIa bound to endothelial cell protein C receptor activates protease activated receptor-1 and mediates cell signaling and barrier protection. Blood (2011) 1.36
Treatment of painful vertebral fractures by kyphoplasty in patients with primary osteoporosis: a prospective nonrandomized controlled study. J Bone Miner Res (2004) 1.34
Bench-to-bedside review: The inflammation-perpetuating pattern-recognition receptor RAGE as a therapeutic target in sepsis. Crit Care (2008) 1.34
Maturing dendritic cells depend on RAGE for in vivo homing to lymph nodes. J Immunol (2008) 1.32
Nucleocytoplasmic shuttling of persistently activated STAT3. J Cell Sci (2007) 1.31
RAGE and Alzheimer's disease: a progression factor for amyloid-beta-induced cellular perturbation? J Alzheimers Dis (2009) 1.31
Chemotactic activity of S100A7 (Psoriasin) is mediated by the receptor for advanced glycation end products and potentiates inflammation with highly homologous but functionally distinct S100A15. J Immunol (2008) 1.30
Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol (2003) 1.30
Endothelial cell protein C receptor cellular localization and trafficking: potential functional implications. Blood (2009) 1.28
Aldehyde dehydrogenase 7A1 (ALDH7A1) is a novel enzyme involved in cellular defense against hyperosmotic stress. J Biol Chem (2010) 1.28
Acute cholesterol depletion impairs functional expression of tissue factor in fibroblasts: modulation of tissue factor activity by membrane cholesterol. Blood (2004) 1.27
The intravertebral vacuum phenomen as specific sign of osteonecrosis in vertebral compression fractures: results from a radiological and histological study. Eur Radiol (2007) 1.27
Proliferation of colo-357 pancreatic carcinoma cells and survival of patients with pancreatic carcinoma are not altered by insulin glargine. Diabetes Care (2008) 1.26
Tyrosine phosphorylation disrupts elongin interaction and accelerates SOCS3 degradation. J Biol Chem (2003) 1.25
The receptor for advanced glycation end products impairs host defense in pneumococcal pneumonia. J Immunol (2009) 1.25
Impaired islet turnover in human donor pancreata with aging. Eur J Endocrinol (2008) 1.24
Activation of tubular epithelial cells in diabetic nephropathy. Diabetes (2002) 1.24
Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc Diabetol (2007) 1.23
Cellular localization and trafficking of tissue factor. Blood (2006) 1.23
Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42/44 MAPK, and nuclear factor kappaB in PBMCs. Diabetes (2003) 1.19
Calcium-phosphate and polymethylmethacrylate cement in long-term outcome after kyphoplasty of painful osteoporotic vertebral fractures. Spine (Phila Pa 1976) (2008) 1.17
Suppression of experimental autoimmune encephalomyelitis by extracellular adherence protein of Staphylococcus aureus. J Exp Med (2006) 1.17
Regulation of neovascularization by human neutrophil peptides (alpha-defensins): a link between inflammation and angiogenesis. FASEB J (2004) 1.17
Cytoprotective signaling by activated protein C requires protease-activated receptor-3 in podocytes. Blood (2011) 1.17
Receptors for advanced glycation end-products targeting protect against hyperoxia-induced lung injury in mice. Am J Respir Cell Mol Biol (2009) 1.16
The adhesive and immunomodulating properties of the multifunctional Staphylococcus aureus protein Eap. Microbiology (2003) 1.16
Proximal neuropathic lesions in distal symmetric diabetic polyneuropathy: findings of high-resolution magnetic resonance neurography. Diabetes Care (2011) 1.16
Endogenous modulators of inflammatory cell recruitment. Trends Immunol (2012) 1.14
Human Thy-1 (CD90) on activated endothelial cells is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18). J Immunol (2004) 1.14
Improvement of islet function in a bioartificial pancreas by enhanced oxygen supply and growth hormone releasing hormone agonist. Proc Natl Acad Sci U S A (2012) 1.14